The Noxopharm (ASX:NOX) share price is jumping 6% after announcing a new CEO

Shares in the ASX biopharm company are rallying this morning.

| More on:
Two lab technicians wearing white coats discuss results they see on a computer screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX: NOX) share price has leapt 6% this morning after announcing a change in executive leadership.

The move coincides with the drug development company's goal to position itself on the global stage.

At the time of writing, the Noxopharm share price is 6.1% higher, at 43.5 cents apiece.

New blood to take the reins

This morning, Noxopharm announced its new year's resolution would be to make 2022 the year of "generational change". It's appointed its current chief medical officer Dr Gisela Mautner as its new CEO.

Dr Mautner will take over from current CEO Dr Graham Kelly from 1 February.

Comment from current CEO

Dr Kelly said Dr Mautner's experience in the industry would equip the company with the ability to position itself for "a valuable partnering opportunity".

Dr Kelly said:

The company is in the process of transiting from an early-stage biotech company into a serious bio-pharma company looking to make its mark on the world stage.

Having worked alongside Gisela for several years now, I have full confidence in her ability to achieve that objective. I believe she will make an outstanding CEO.

Dr Kelly will transition from an executive to a consultant role. In doing so, he will remain involved in the company's future — remaining its largest shareholder, board member, and inventor of much of the company's Intellectual Property.

Noxopharm is an Australian based biopharmaceutical company with the primary focus of treating cancer and septic shock.

The company is developing its lead drug candidate Veyonda, currently in the second phase of its clinical trials.

Noxopharm share price snapshot

In 2021, the Noxopharm share price dropped by around 20%. It saw its sharpest drop in mid-December, just a few days after enrolling the first group of patients for the first clinical trial of Veyonda as an experimental cancer treatment.

The drop marked the share price's 52-week low.

As of today, the company has a market capitalisation of more than $125 billion with around 292 million shares issued.

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

a young woman looks happily at her phone in one hand with a selection of shopping bags in her other hand.
BNPL shares

Up 87% since April, why the Zip share price can keep flying higher into 2026

A leading fund manager expects more outsized gains from Zip shares ahead.

Read more »

Man in mining hat with fists raised and eyes closed looking happy and excited about the Newcrest share price
Share Market News

Why BHP and these ASX dividend stocks are buys

The mining giant and these shares have been named as buys by brokers.

Read more »

a woman holds her finger to the side of her face and looks upwards as she thinks about something.
Share Market News

Where to invest when the ASX 200 hits an all time high?

With the ASX creeping towards a record high, here are some options to consider

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Share Market News

5 things to watch on the ASX 200 on Friday

Will the market end the week on a positive note? Let's find out.

Read more »

Young man with a laptop in hand watching stocks and trends on a digital chart.
Share Market News

Which investment trends drove equity markets in May according to Macquarie?

The ASX 200 increased 4.2% in May.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Opinions

Too high? These 2 ASX shares might be due for a correction

These popular blue chips are looking dicey to me.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »